Figure 1: The levels of RANKL after treatment with 1,25(OH)2D3, MTX, and 1,25(OH)2D3 plus MTX in RA patients. The RA patients’ PBMCs are treated with either anti-CD3/CD28, or 1,25(OH)2D3, MTX at various concentrations, or the combination of 1,25(OH)2D3 and MTX (D2M2 group). The levels of RANKL were detected and significantly decreased in the groups of 1,25(OH)2D3  and MTX compared to those of the group of anti-CD3/CD28 ( ). There was no difference in RANKL expression between the group of D2M2 and the group of Anti-CD3/CD28. *Mean .